The ACEIs or ARBs may particularly use in COVID-19 hypertensive patients to manage hypertension and other cardiovascular diseases where it is assumed that using ACEIs/ARBs in COVID-19 patients may upregulate ACE2 enzyme which in turn may protect organ damage and may reduce associated death as well. This evidence concerns the gene ACE2 and hypertensive disorder.